Search

Your search keyword '"Paul Kwo"' showing total 11 results
Start Over Author "Paul Kwo" Publisher elsevier bv
11 results on '"Paul Kwo"'

5. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study

Author

Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan Nguyen, Eugene R. Schiff, Hie-Won Hann, Douglas Dieterich, Ronald Nahass, James Park, Sing Chan, Steven-Huy Han, Edward Gane, Michael Bennett, Katia Alves, Hany Zayed, Qi Huang, Richard Colonno, Steven Knox, Luisa Stamm, Maurizio Bonacini, Ira Jacobson, Walid Ayoub, Frank Weilert, Natarajan Ravendhran, Alnoor Ramji, Paul Kwo, Magdy Elkhashab, Tarek Hassanein, Ho Bae, Jacob Lalezari, Scott Fung, and Mark Sulkowski

Subjects
Hepatology
Published
2020
Full Text
View/download PDF

9. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

Author

Michael Charlton, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis, Robert S. Brown, Michael W. Fried, Norah A. Terrault, Jacqueline G. O'Leary, Hugo E. Vargas, Alexander Kuo, Eugene Schiff, Mark S. Sulkowski, Richard Gilroy, Kymberly D. Watt, Kimberly Brown, Paul Kwo, Surakit Pungpapong, Kevin M. Korenblat, Andrew J. Muir, Lewis Teperman, Robert J. Fontana, Jill Denning, Sarah Arterburn, Hadas Dvory-Sobol, Theo Brandt-Sarif, Phillip S. Pang, John G. McHutchison, K. Rajender Reddy, Nezam Afdhal, Michael Fried, Kris Kowdley, Norah Terrault, Steve Flamm, John Lake, Greg Everson, Mark Sulkowski, Michael Curry, Rajender Reddy, Hugo Vargas, Andrew Muir, Atif Zaman, Robert Fontana, Jacqueline O'Leary, Obaid Shaikh, Kevin Korenblat, Richard Stravitz, Kymberly Watt, Narayanan Menon, James Bredfeldt, and Carlos Romero-Marrero

Subjects
Liver Cirrhosis, Male, Ledipasvir, medicine.medical_specialty, Time Factors, Cirrhosis, Genotype, Sofosbuvir, Hepatitis C virus, medicine.medical_treatment, Hepatitis C Virus Infection, Cholestasis, Intrahepatic, Hepacivirus, Liver transplantation, medicine.disease_cause, Antiviral Agents, Gastroenterology, chemistry.chemical_compound, Liver disease, Model for End-Stage Liver Disease, Internal medicine, Fibrosing Cholestatic Hepatitis, Ribavirin, medicine, Humans, Fluorenes, Hepatology, business.industry, Hepatitis C, Chronic, Middle Aged, medicine.disease, United States, Surgery, Liver Transplantation, Drug Combinations, Treatment Outcome, chemistry, Disease Progression, Benzimidazoles, Drug Therapy, Combination, Female, Uridine Monophosphate, business, medicine.drug, Decompensated Cirrhosis
Abstract

Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. Methods In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin in patients infected with HCV genotypes 1 or 4. Cohort A enrolled patients with cirrhosis and moderate or severe hepatic impairment who had not undergone liver transplantation. Cohort B enrolled patients who had undergone liver transplantation: those without cirrhosis; those with cirrhosis and mild, moderate, or severe hepatic impairment; and those with fibrosing cholestatic hepatitis. Patients were assigned randomly (1:1) to receive 12 or 24 weeks of a fixed-dose combination tablet containing ledipasvir and sofosbuvir, once daily, plus ribavirin. The primary end point was sustained virologic response at 12 weeks after the end of treatment (SVR12). Results We enrolled 337 patients, 332 (99%) with HCV genotype 1 infection and 5 (1%) with HCV genotype 4 infection. In cohort A (nontransplant), SVR12 was achieved by 86%–89% of patients. In cohort B (transplant recipients), SVR12 was achieved by 96%–98% of patients without cirrhosis or with compensated cirrhosis, by 85%−88% of patients with moderate hepatic impairment, by 60%–75% of patients with severe hepatic impairment, and by all 6 patients with fibrosing cholestatic hepatitis. Response rates in the 12- and 24-week groups were similar. Thirteen patients (4%) discontinued the ledipasvir and sofosbuvir combination prematurely because of adverse events; 10 patients died, mainly from complications related to hepatic decompensation. Conclusion The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation. ClinTrials.gov: NCT01938430.

Published
2015
Full Text
View/download PDF

10. SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C

Author

Joseph Gathe, Peter Jones, Ariel Porcalla, Federico J. Mensa, Lisa Barcomb, Paul Kwo, Yao Yu, Peter Toth, and Douglas E. Dylla

Subjects
0301 basic medicine, medicine.medical_specialty, Statin, business.industry, medicine.drug_class, 030106 microbiology, nutritional and metabolic diseases, Glecaprevir, Pibrentasvir, Virus, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Concomitant, Internal medicine, Medicine, lipids (amino acids, peptides, and proteins), 030211 gastroenterology & hepatology, Rosuvastatin, Cardiology and Cardiovascular Medicine, business, Pravastatin, medicine.drug
Abstract

Some statins are not recommended for concomitant use with glecaprevir/pibrentasvir (G/P) treatment for chronic hepatitis C virus infection. We analyzed the impact of switching to rosuvastatin or pravastatin compared to maintaining or interrupting current statin use. Safety and efficacy data from

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results